Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022 06:00 ET
|
Immuron Limited
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in...
Immuron North American Travelan® Sales up 494% and Global sales up 431%
July 11, 2022 06:00 ET
|
Immuron Limited
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11,...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
May 09, 2022 06:00 ET
|
Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
Immuron Travelan® Global sales up 216%
April 27, 2022 06:00 ET
|
Immuron Limited
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. ...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
April 19, 2022 07:33 ET
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
January 13, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
January 12, 2022 06:00 ET
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
November 15, 2021 06:00 ET
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
April 20, 2020 06:00 ET
|
Immuron Limited
Key Highlights: North American sales up by 95% YoY in Q3 FY20Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57%...
U.S. Defense Reports Immuron’s Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers’ diarrhea
September 04, 2019 06:00 ET
|
Immuron Limited
Key Highlights: Major goal of study was to evaluate Travelan®’s ability to bind and react to a variety of infectious Vibrio cholera strains from Southeast Asia Pathogenic bacteria evaluated in study...